Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation

Pertussis is still observed in many countries despite of high vaccine coverage. Acellular pertussis (aP) vaccination is widely implemented in many countries as primary series in infants and as boosters in school-entry/adolescents/adults (including pregnant women in some). One novel strategy to impro...

Full description

Bibliographic Details
Main Authors: Floriane Auderset, Marie Ballester, Beatris Mastelic-Gavillet, Paola Fontannaz, Martine Chabaud-Riou, Nathalie Reveneau, Marie Garinot, Noëlle Mistretta, Yuanqing Liu, Paul-Henri Lambert, Martina Ochs, Claire-Anne Siegrist
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-07-01
Series:Frontiers in Immunology
Subjects:
vaccine
pertussis
adjuvant
TLR9 agonist
TLR4 agonist
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01520/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01520/full

Similar Items